Contrast Media & Molecular Imaging · 2016 · 17 citations · 23 references
MedicineNuclear MedicineOncologyMolecular ImagingMolecular OncologyTherapeutic Nuclear MedicineHepatobiliary ImagingOncologic Nuclear ImagingPositron Emission TomographyRadiotracer DevelopmentTargeted Imaging AgentsTumor ImagingHepatic Tumor ImagingHepatobiliary RadiopharmaceuticalsHepatocellular Carcinoma ImagingHepatocellular Carcinoma MetastasisPet RadiopharmaceuticalsRadioisotope LabelingRadiotracer SynthesisTumor Radiotracer Imaging
The goal of this study is to evaluate a new (18) F-labeled imaging agent for diagnosing high metastatic (aggressive) hepatocellular carcinoma using positron emission tomography (PET). The new (18) F-labeled imaging agent [(18) F]AlF-NOTA-G-TMTP1 was synthesized and radiolabeled with (18) F using NOTA-AlF chelation method. The tumor-targeting characteristics of [(18) F]AlF-NOTA-G-TMTP1 was assessed in HepG2, SMCC-7721, HCC97L and HCCLM3 xenografts. The total synthesis time was about 20 min with radiochemical yield of 25 ± 6%. The specific activity was about 11.1-14.8 GBq/µmol at the end of synthesis based on the amount of peptide used and the amount of radioactivity trapped on the C18 column. The log P value of [(18) F]AlF-NOTA-G-TMTP1 was -3.166 ± 0.022. [(18) F]AlF-NOTA-G-TMTP1 accumulated in SMCC-7721 and HCCLM3 tumors (high metastatic potential) in vivo and result in tumor/muscle (T/M) ratios of 4.5 ± 0.3 and 4.7 ± 0.2 (n = 4) as measured by PET at 40 min post-injection (p.i.). Meanwhile, the tumor/muscle (T/M) ratios of HepG2 and HCC97L tumors (low metastatic potential) were1.6 ± 0.3 and 1.8 ± 0.4. The tumor uptake of [(18) F]AlF-NOTA-G-TMTP1 could be inhibited 61.9% and 57.6% by unlabeled G-TMTP1 in SMCC-7721 and HCCLM3 xenografts at 40 min p.i., respectively. Furthermore, [(18) F]AlF-NOTA-G-TMTP1 showed pretty low activity in the liver and intestines in all tumor bearing mice, such in vivo distribution pattern would be advantageous for the detection of hepatic carcinoma. Overall, [(18) F]AlF-NOTA-G-TMTP1 may specifically target high metastatic or/and aggressive hepatocellular carcinoma with low background activity and, therefore, holds the potential to be used as an imaging agent for detecting tumor lesions within the liver area. Copyright © 2016 John Wiley & Sons, Ltd.
23
Major Causes of Death among Men and Women in China
Jiang He, Dongfeng Gu, Xigui Wu et al. · New England Journal of Medicine · 2005 · 1.2K citations
Public Health, Geriatric Medicine, Population Health Sciences +17
A Novel Method of <sup>18</sup>F Radiolabeling for PET
William J. McBride, Robert M. Sharkey, Habibe Karacay et al. · Journal of Nuclear Medicine · 2009 · 408 citations · Full text
Pharmacy, Biochemistry, Chemistry +14